Menu

Fast-Track Peer Review Controversy

An editor of the journal Scientific Reports quits in protest of paid, expedited review.

Mar 31, 2015
Jef Akst

FLICKR, ANONYMOUS ACCOUNTBiogeographer Mark Maslin of University College London (UCL) announced his resignation from his positions as volunteer editor and member of the editorial advisory panel at Scientific Reports, a Nature Publishing Group (NPG) open-access journal, in a tweet last week (March 26) after the journal announced it is instituting a policy that would allow authors to pay for expedited peer review by a private company.

“My objections are that it sets up a two-tiered system and instead of the best science being published in a timely fashion it will further shift the balance to well-funded labs and groups,” Maslin told ScienceInsider. “Academic publishing is going through a revolution and we should expect some bumps along the way. This was just one that I felt I could not accept.”

Private peer review is now a multimillion dollar industry, with many journals now offering a service through which authors can fast-track their manuscripts through the process—for a price. Last week (March 24), Scientific Reports announced that, for a cost of $750, it had begun offering such expedited service, through the peer-review service Rubriq, which pays its editors $100 each per review. (Rubriq also offers pre-review services for researchers looking for feedback before submitting to a journal.)

Nandita Quaderi, NPG’s publishing director, defended the new program on the Nature blog Of Schemes and Memes. “Needless to say, an author choosing the fast-track option is only benefiting from a quicker decision,” Quaderi wrote. “The introduction of this service has no bearing on our editorial decision process.”

But Maslin, at least, was concerned enough to quit. “Deep consideration and a well thought out review is much more important than its speed,” he told ScienceInsider. “I have had brilliant reviews which have considerably improved my papers, and I really appreciated all the time taken.”

And he isn’t alone. “I worry about it in terms of the outcome it would have,” fellow UCL researcher Georgina Mace, also a member of the Scientific Reports editorial advisory panel, told Nature. “In some areas of science, people have access to money they can use for that sort of thing and other areas don’t. . . . I do worry about this two-tier thing.”

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

IDT and Washington University join forces to increase access to the latest NGS technologies
IDT and Washington University join forces to increase access to the latest NGS technologies
As part of its commitment to advocate for the genomics age, Integrated DNA Technologies (IDT) aims to lower the barriers to access the latest NGS technologies.
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.
DeNovoMAX - NRGene's new genomics tool to meet a major agbio need:
DeNovoMAX - NRGene's new genomics tool to meet a major agbio need:
NRGene has launched a new product that aims to empower breeding and maximize agricultural yield as part of the Denovo assembly product suite offered by the company.
Overcoming the Efficiency Challenge in Clinical NGS
Overcoming the Efficiency Challenge in Clinical NGS
Download this white paper to see how an ECS lab serving a network of more than 10,000 healthcare providers integrated QIAGEN Clinical Insight (QCI) Interpret to significantly reduce manual variant curation efforts and increase workflow efficiency by 80%!